MX2013007146A - Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. - Google Patents

Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes.

Info

Publication number
MX2013007146A
MX2013007146A MX2013007146A MX2013007146A MX2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A
Authority
MX
Mexico
Prior art keywords
oprf
hospitalized
patients
agents
carboxy
Prior art date
Application number
MX2013007146A
Other languages
English (en)
Spanish (es)
Inventor
Christoph Klade
Robert Schlegl
Kerstin Westritschnig
Original Assignee
Intercell Austria Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria Ag filed Critical Intercell Austria Ag
Publication of MX2013007146A publication Critical patent/MX2013007146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013007146A 2010-12-23 2011-03-18 Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. MX2013007146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
MX2013007146A true MX2013007146A (es) 2013-11-01

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007146A MX2013007146A (es) 2010-12-23 2011-03-18 Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes.

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EP3185897A4 (en) * 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
CN107922482A (zh) 2015-05-01 2018-04-17 英伊布里克斯有限合伙公司 Iii型分泌系统靶向分子
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20040197341A1 (en) * 2001-09-03 2004-10-07 Jean-Claude Pechere Therapeutic process for p. aeruginosa infections using macrolide antibiotics
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
US9987344B2 (en) * 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Also Published As

Publication number Publication date
ZA201304235B (en) 2014-09-25
AU2011348396A1 (en) 2013-07-04
EP2655402A1 (en) 2013-10-30
CA2822684A1 (en) 2012-06-28
CN103270047A (zh) 2013-08-28
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
BR112013016254A2 (pt) 2017-07-11
JP5893640B2 (ja) 2016-03-23
KR20130133212A (ko) 2013-12-06
WO2012084272A1 (en) 2012-06-28
AU2011348396A2 (en) 2013-07-11
JP2014504297A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
CU20120095A7 (es) Antagonistas de pcsk9
WO2008121615A3 (en) Antibody formulation
WO2014022679A3 (en) Anti-etbr antibodies and immunoconjugates
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
CL2013003640A1 (es) Proteina de union a il-17, construccion que comprende dicha proteina, un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de dicha proteina; acido nucleico que la codifica; vector; celula huesped, metodo de produccion; composicion que la comprende; y su uso para reducir la actividad de la il-17 en una patologia en la cual il-17 es perjudicial (div.sol.2129-11).
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
EA201171494A1 (ru) Миметики белка smac
AR075908A1 (es) Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo.
PH12014501988A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
NZ602220A (en) Antibodies with ph dependent antigen binding
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
PH12015500196B1 (en) Methods of treating a tauopathy
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
BR112013023006A2 (pt) formulações de suspensões não aquosas de anticorpos de alta concentração e viscosidade reduzida
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
MX365567B (es) Formulaciones de anticuerpo.
WO2011137243A3 (en) Fluorescent fusion polypeptides and methods of use
EA201390467A1 (ru) Композиции антител и способы применения
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Owner name: MERCK SHARP & DOHME B.V.

FA Abandonment or withdrawal